Retrospective Analysis Of Promoter Polymorphism Of UGT1A1 Gene In Cancer Patients Enrolled On Clinical Trials With Flavopiridol At National Cancer Institute To Assess The Pharmacokinetics And Pharmacodynamics Of Flavopiridol
- Determine the relationship between UGT1A1 genotypes and drug pharmacokinetics and
occurrence of gastrointestinal toxicity in cancer patients previously treated with
flavopiridol on protocol NCI-97-C-0171C.
OUTLINE: Genomic DNA from pre-existing samples of serum or plasma from each patient is
analyzed for UGT1A1 gene by polymerase chain reaction and DNA sequencing. Results are then
analyzed for a possible association between UGT1A1 genotypic variation and susceptibility to
Patients do not receive the results of the genetic testing, and the results do not influence
the type or duration of treatment.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
William D. Figg, PharmD
National Cancer Institute (NCI)
United States: Federal Government
|Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support||Bethesda, Maryland 20892-1182|